If this pans out, it will be a big WOW! Endocrine Today is reporting that umbilical cord blood stem cells have enabled diabetes patients to reduce insulin intake. From the story:
Umbilical cord blood stem cells have been successful in the treatment of type 1 diabetes, according to a press release from Cord Blood America Inc. The stem cells have been used to re-instruct T cells so that the pancreas will begin producing insulin again, thereby reducing the amount of injected insulin needed. According to the release, the treatment was successful in long-time diabetes patients believed to have no insulin-producing ability.
Results from a phase 1/phase 2, open-label clinical trial published in the January issue of BMC Medicine demonstrated that Stem Cell Educator, an in vivo cord blood stem cell treatment, reversed autoimmunity and promoted the regeneration of islet beta cells in patients with type 1 diabetes. “Successful immune modulation by cord blood stem cells and the resulting clinical improvement in patient status may have important implications for other autoimmune and inflammation-related diseases without the safety and ethical concerns associated with conventional stem cell-based approaches,” the researchers wrote. The study, conducted in China, included 15 patients at a median age of 29 years and a median diabetic history of 8 years.
This is very exciting, but remember, it is a small, preliminary study. Let’s hope this apparent success pans out in further research.
Dear Reader,
You have a decision to make: double or nothing.
For this week only, a generous supporter has offered to fully match all new and increased donations to First Things up to $60,000.
In other words, your gift of $50 unlocks $100 for First Things, your gift of $100 unlocks $200, and so on, up to a total of $120,000. But if you don’t give, nothing.
So what will it be, dear reader: double, or nothing?
Make your year-end gift go twice as far for First Things by giving now.
